←
Ambry Genetics9,050 posts
Ambry Genetics avatar

Ambry Genetics

@AmbryGenetics

As a company built by scientists, genetic counselors and physicians, Ambry, a Tempus company, is your partner in #genetics and #genomics.

◷ Joined February 2010▧ 3,966 Photos and videos
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Nov 13

Dr. Kristin Kohler recently joined ASCO's JCO Precision Oncology Conversations with her co-authors to share insights from "Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk." These findings provide new insights into the molecular and clinical heterogeneity of germline deletions involving EPCAM. Listen now: hubs.ly/Q04FfbbG0

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Nov 12

Today is #GeneticCounselorAppreciationDay! We are so grateful for the dedicated clinical GCs we work with to bring answers to more patients as well as our internal GCs, who are integral to the work we do. We are continually inspired by this dedicated and passionate group of professionals. Please join us in thanking Genetic Counselors for their important work.

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Nov 10

Join us for a webinar on 11/12 to hear from Seth Berger and Susan Toomey as they trace the evolution of rare disease genomics through the NHGRI-funded GREGoR Consortium and the Pediatric Mendelian Genomics Research Center (PMGRC) at UC Irvine. Through real-world patient case studies, attendees will explore how LR-WGS turns diagnostic cold cases into definitive molecular answers. Discover how collaborative research models and advanced genomic profiling are transforming diagnostics for unsolved rare diseases. Register now: hubs.ly/Q04DTSYl0

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Nov 9

We can't wait to see you this week at #NSGC26! Visit Booth 1169 to explore how we’re delivering true diagnostic intelligence—from our comprehensive testing compendium and vast, representative databases driving equity at scale, to seamless EHR integration paired with lab-driven reanalysis. Find more information, including a list of our scientific posters here: hubs.ly/Q04DPD780

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Nov 7

For three decades, we’ve been honored to support your genetic care and pedigree needs. Come visit us at #NSGC booth 1169 for an exclusive sneak peek at the next generation of Progeny! What is your favorite Progeny memory from over the years? Share your stories in the comments below! #CheersTo30YearsofPedigrees

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Nov 6

By leveraging Ambry’s large-scale testing database, our new study in Familial Cancer evaluated the largest cohort of APC I1307K homozygotes to date (n=74, compared to prior series of just 4). While homozygotes demonstrated a trend toward increased colorectal cancer odds compared to wildtype (OR: 2.48), the risk appeared far more modest than MSH6-associated Lynch syndrome. Read the open-access manuscript here: hubs.ly/Q04DsMbs0

Post attachment
Inside Precision Medicine avatar
⟳ Ambry Genetics retweeted
Inside Precision Medicine@Inside_PM·Oct 16

Whole-Genome Diagnostics Evolve with RNA and Pangenome Integration @AmbryGenetics' GenomeNext test uncovers rare diseases with more comprehensive sequencing, diverse genomic references, and ongoing reanalysis #genetictesting #WGS #DNA #rarediseases hubs.li/Q04BpK790

Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Nov 2

A "one-size-fits-all" approach to variant interpretation can inadvertently widen health disparities. Our latest study found that cancer risks in CDKN2A heterozygotes differs across racial and ethnic groups, which can impact the clinical evidence leveraged for variant classification. Read more about how factoring race and ethnicity into variant assessment workflows can prevent misclassification of pathogenic variants in underrepresented populations. #HereditaryCancer #GeneChat #GeneticTesting #VariantAssessment #HealthEquity hubs.ly/Q04CH2V00

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 30

GenomeReveal enables the addition of RNA testing for eligible variants into genome sequence analysis, improving the ability to classify variants that are predicted to impact the splicing process. The integration of RNA sequencing to Ambry’s genome sequencing test enhances diagnostic precision and expands the ability to uncover critical insights for rare disease patients and their families. Learn more: hubs.ly/Q04BM9gS0

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 28

Join us for a webinar with Ambry's TJ Slavin, M. D., Chief Medical Officer. Ambry is setting a new bar for clinical whole genome sequencing by delivering unprecedented clarity, maximizing diagnostic yield, and driving equitable care across diverse patient populations. In this session, you'll discover how Ambry helps clinicians get the most out of every genome test. Register now: hubs.ly/Q04Bkc0f0

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 26

Today is #VariantScientistsAppreciationDay and we want to take this time to thank our incredible variant scientists for their relentless commitment to scientific excellence and patient care. Please join us in celebrating these experts whose work transforms complex data into clear answers.

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 26

What is the true power of a pangenome reference for clinical care? More answers for ALL patients. Most genomic testing relies on a single linear reference genome, GenomeNext™️ leverages a pangenome reference, delivering improved test accuracy, comprehensive genomic analysis, and more equitable answers for every family[1]. [1] Hickey G, Monlong J, Ebler J, et al. Pangenome graph construction from genome alignments with Minigraph-Cactus. Nat Biotechnol. 2024;42(4):663-673. doi: 10.1038/s41587-023-01793-w.

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 23

Ambry Genetics is a proud sponsor of the #SDBP2026 annual meeting. Attend our poster presentation, "Dual Diagnoses from Exome Sequencing in Patients with Trisomy 21," on Saturday, Oct 24, 2026 6:00pm – 7:15pm. Visit our booth to learn how our tests can help you and your patients find clearer answers sooner – because every day without a diagnosis matters.

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 22

A diagnosis can be the beginning of a lifelong journey. Our commitment to patient support extends to our whole genome sequencing with Patient for Life™️. Proactive, continuous reanalysis of genetic data done automatically without provider requests. - New answers, not just reclassifications – When new gene–disease associations are discovered, we proactively review all past cases so even a previous “negative” can become a new diagnosis. - Amended reports, automatically – We continuously search in the background and update reports when new information emerges, so patients get answers without providers needing to request them. - Post-test genetic counseling – Expert guidance to help you understand your results and any updates along the way. Experience our commitment to lifelong support: hubs.ly/Q04B3y120 #PatientForLife #WholeGenome #PatientSupport # #FamilySupport

Post attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 22

From research on MAVEs to secondary findings to deep intronic variants, Day 1 at #ASHG26 sparked incredible conversations at our posters.  Thank you to everyone who stopped by to connect with our team! If you missed any of today’s presentations, you can explore all our posters here: hubs.ly/Q04C1Vyh0

Post attachmentPost attachmentPost attachment
Ambry Genetics avatar
Ambry Genetics@AmbryGenetics·Oct 20

Join us for a live webinar on 10/29 at 11 AM PDT to learn how clinician-advocacy collaborations drive improved patient outcomes while fostering meaningful professional growth, learning, and career enrichment. Register now: hubs.ly/Q04BM3Jm0 *This live webinar is eligible for CE credit. A recorded version will be available for CE credit on our website.

Post attachment